. Author manuscript; available in PMC: 2008 Jun 13.

Published in final edited form as: J Infect Dis. 2006 Nov 8;194(12):1638–1649. doi: 10.1086/509258

Table 2.

Local reactogenicity.

		Vaccine recipients
	Placebo recipients	10⁹ PUs	10¹⁰ PUs	10¹¹ PUs
Local symptoms, intensity	(n = 6)	(n = 10)	(n = 10)	(n = 10)
Pain/tenderness
None	4 (66.7)	8 (80)	3 (30)	0 (0)
Mild	2 (33.3)	2 (20)	7 (70)	9 (90)
Moderate	0 (0)	0 (0)	0 (0)	1 (10)
Severe	0 (0)	0 (0)	0 (0)	0 (0)
Swelling
None	6 (100)	10 (100)	9 (90)	10 (100)
Mild	0 (0)	0 (0)	1 (10)	0 (0)
Moderate	0 (0)	0 (0)	0 (0)	0 (0)
Severe	0 (0)	0 (0)	0 (0)	0 (0)
Erythema
None	6 (100)	10 (100)	7 (70)	9 (90)
Mild	0 (0)	0 (0)	3 (30)	1 (10)
Moderate	0 (0)	0 (0)	0 (0)	0 (0)
Severe	0 (0)	0 (0)	0 (0)	0 (0)
Any local symptom
None	4 (66.7)	8 (80)	2 (20)	0 (0)
Mild	2 (33.3)	2 (20)	8 (80)	9 (90)
Moderate	0 (0)	0 (0)	0 (0)	1 (10)
Severe	0 (0)	0 (0)	0 (0)	0 (0)

NOTE. Data are no. (%) of subjects. Each subject was counted once for the worst severity recorded during the 5 days after vaccination. PUs, particle units.